Treatment of Sialorrhea with Botulinum Toxin A Injection in Children

Basit Öğe Kaydı
dc.contributor.authorTure, E.
dc.contributor.authorYazar, A.
dc.contributor.authorDundar, M. A.
dc.contributor.authorBakdik, S.
dc.contributor.authorAkin, F.
dc.contributor.authorPekcan, S.
dc.date.accessioned2024-02-23T14:37:55Z
dc.date.available2024-02-23T14:37:55Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractAims: We aimed to evaluate the effectivity and safety of botulinum toxin A (BT-A) to reduce sialorrhea in children with hypersalivation due to neurological diseases. Methods: Patients who had a complaint of severe sialorrhea were included in the study. Drooling severity of the patients was evaluated using the classification of Thomas-Stonell and Greenberg. The frequency of aspiration before and after the procedure was recorded. The 24-hour saliva amount and mean duration of two consecutive aspirations were recorded. BT-A was injected into the bilateral parotid and submandibular glands by a otorhinolaryngologist under the guidance of ultrasound guidance (USG). Results: When patients' mean drooling severity scores, drooling frequency scores, mean duration of two consecutive aspirations, and amount of saliva collected before and after procedure were compared, a statistical significance was observed. One-year hospital records before after and injection were examined and it was observed that after BT-A injection, hospital visits were statistically significantly low (P = 0.017). Conclusion: BT-A injection into salivary glands is well tolerated, is minimally invasive, has low complication rates and should be performed into both parotid and submandibular glands under USG. Although there is still no consensus on the ideal dose and frequency of injections, it is thought that a dose of 1U/kg/gland can be used with safety in pediatric age groups and the dimensions of the salivary glands and quantitative measurements of the amount of saliva should be utilized. Larger studies involving more patients are required in order to constitute a standard injection protocol.en_US
dc.identifier.doi10.4103/njcp.njcp_85_20
dc.identifier.endpage852en_US
dc.identifier.issn1119-3077
dc.identifier.issue6en_US
dc.identifier.pmid34121732en_US
dc.identifier.scopus2-s2.0-85108235059en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage847en_US
dc.identifier.urihttps://doi.org/10.4103/njcp.njcp_85_20
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16284
dc.identifier.volume24en_US
dc.identifier.wosWOS:000664861300010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofNigerian Journal Of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBotulinum Toxin Aen_US
dc.subjectChilden_US
dc.subjectDroolingen_US
dc.subjectNeurological Diseasesen_US
dc.subjectSialorrheaen_US
dc.titleTreatment of Sialorrhea with Botulinum Toxin A Injection in Childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu